Shots:

• The companies collaborated to evaluate the Evaxion’s EVX-01 + MSD’s Keytruda in P-IIb study in patients with metastatic melanoma stage III & IV. The trial is expected to start in Q4’21 & will investigate the personalized neoepitope immunotherapy
• Evaxion will be responsible for conducting the study & MSD will be responsible to supply all of the necessary Keytruda and will continue in collaboration
• EVX-01 is also being evaluated in a P-I/IIa trial for patients with melanoma based on Evaxion’s PIONEER AI technology. As reported in July- the P-I/IIa data showed that EVX-01 could improve the treatment landscape in melanoma and other cancers

 ­ | Ref: GlobeNewswire | Image: Shutterstock